CDC 2017-18 Influenza Vaccine Recommendations

The Centers for Disease Control and Prevention (CDC) has issued the recommendations of the Advisory Committee on Immunization Practices (ACIP) for the 2017-18 influenza season. The CDC continues to recommend routine annual influenza vaccination for all persons aged ≥6 months who do not have contraindications. Standard dose or high dose vaccine is acceptable for adults aged ≥65 years. Among the changes from last year:

  • Vaccine viruses included in the 2017–18 US trivalent influenza vaccines will be an A/Michigan/45/2015 (H1N1)pdm09–like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008–like virus (Victoria lineage). Quadrivalent influenza vaccines will contain these 3 viruses and an additional influenza B vaccine virus, a B/Phuket/3073/2013–like virus (Yamagata lineage).
  • Afluria Quadrivalent and Flublok Quadrivalent are now available for patients aged ≥18 years, and there is an expansion of the age indication for FluLaval Quadrivalent, previously licensed for ≥3 years, to ≥6 months.
  • Pregnant women may receive any licensed, recommended, age-appropriate influenza vaccine.
  • FluMist Quadrivalent should not be used during the 2017–18 season due to concerns about its effectiveness against influenza A(H1N1)pdm09 viruses in the US during the 2013–14 and 2015–16 influenza seasons.
Summary
Article Name
CDC 2017-18 Influenza Vaccine Recommendations
Description
The CDC continues to recommend routine annual influenza vaccination for all persons aged ≥6 months who do not have contraindications. Standard dose or high dose vaccine is acceptable for adults aged ≥65 years.
Author
Publisher
Aurelian Ivan MD
Publisher Logo